US 12178806 B1Patent grantUnited States

Apoptosis-Focused Cancer Cell Screening Compound

Official patent title

Method for contacting cancer cells with antitumor agent and apoptotic inducer

Arabic title: طريقة لملامسة الخلايا السرطانية بعامل مضاد للأورام ومحفز للاستموات

Invention

Problem

Cancer research requires additional candidate compounds that can inhibit malignant-cell growth through defined mechanisms, while providing a reproducible synthesis and a basis for preclinical evaluation.

Why it matters

New, well-characterized chemical candidates can expand the set of molecules available for studying apoptosis and for deciding whether further oncology development is justified.

Approach

The patent discloses a thiazolidinedione compound of Formula I, its reflux synthesis, and methods of contacting cancer-cell lines with the compound to inhibit growth through apoptosis-related pathways.

Who may benefit

Potential beneficiaries are medicinal-chemistry groups, cancer-biology laboratories, pharmaceutical research teams, and technology-transfer partners evaluating early-stage oncology assets.

Potential value

The asset links a defined compound-preparation route with reported in-vitro activity across several cancer-cell lines and named apoptosis-associated pathways, creating a focused package for preclinical follow-up.

Background

Cancer treatment research increasingly examines combinations and targeted mechanisms in addition to surgery, radiation, and conventional chemotherapy. Apoptosis is a regulated cell-death process involving factors such as p53, BAX, caspases, BCL-2, MMP2, and MMP9, and its control is a frequent focus of anticancer discovery. The patent responds to the need for further chemical candidates by describing a thiazolidinedione derivative, a preparation method, and cell-contact experiments. The evidence is preclinical and cell-based; it does not establish efficacy or safety in animals or humans.

Technology overview

Formula I is prepared by dissolving 3-(2-(1,3-dioxoisoindolin-2-yl)ethyl)thiazolidine-2,4-dione and 2-hydroxy-5-nitrobenzaldehyde in a polar protic solvent, adding an acid and a heterocyclic amine, and refluxing for 6–10 hours. The patent reports an 83–87% synthesis yield and in-vitro growth-inhibition or IC50 measurements in A549, HCT116, PC3, FaDu, MDA-MB-468, and HeLa cells at specified concentrations. It also names apoptosis-related pathways and describes carrier-containing dosage forms, but no clinical use is established.

Potential applications

Potential use as a lead compound in preclinical anticancer drug-discovery programs.
Potential use in in-vitro studies of apoptosis-associated signaling pathways.
Potential use as a reference candidate in comparative cancer-cell assays.
Potential use in formulation and medicinal-chemistry optimization studies.

Evidence-supported advantages

Provides a specified multi-step synthesis with reported reaction time and yield.
Reports testing across multiple named cancer-cell lines rather than a single model.
Connects the observed cell response to several named apoptosis-associated pathways.
Defines concentrations, growth-inhibition ranges, and selected IC50 ranges for follow-up.

Development stage

Patent publication with reported compound synthesis and in-vitro cell-line testing; animal efficacy, clinical safety, regulatory status, and commercialization were not established.

Commercial opportunity

The compound and synthesis package may be suitable for licensing into a preclinical oncology program or for sponsored validation with a medicinal-chemistry partner. Advancement would require independent structure confirmation, selectivity and toxicity studies, pharmacology, animal efficacy, formulation work, clinical trials, and regulatory review.

Patent classifications

WIPO IPC

A61K31/427Preparations for medical, dental or toiletry purposes

CPC

A61K31/427Preparations for medical, dental or toiletry purposes

Inventors

First inventorTarek Ahmed Yousef
InventorSaad Shaaban
InventorAhmed A. Al-Karmalawy
InventorMarwa Sharaky

Keywords

thiazolidinedione
cancer cells
apoptosis
Formula I
in-vitro assay
IC50
medicinal chemistry

Patent document and drawings

The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.